Investors
Click here for Proxy Materials and Annual Meeting InformationAlnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi, a completely new approach to drug discovery and development. RNAi is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNA
More >>Latest News
06/06/13
Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2013--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, today announced that management will present a company overview
at the Goldman Sachs 34th Annual Global Healthcare Conference
on Thursday, June 13, 2013 at 10:40 a.m. PT (1:40 p.m. ET) at the
Terranea Resort in Rancho Palos Verdes, Calif.
A live audio webcast of the presentation will be available on the News ... |
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Financial Tear Sheet
